First-in-Human T1D Vaccine Trial Reports Positive Results
A first-in-human study of the coxsackie B vaccine—made by Breakthrough T1D-funded researchers Drs. Hyoty and Knip—reports positive results.
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning…
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of…
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world…
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him…
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have…
FDA Breakthrough Therapy Designation for TTP399—A Potential First-in-Class Adjunct Therapy in T1D
The FDA granted Breakthrough Therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for T1D.
Severe Low Blood Sugar: There’s a New Treatment Option
The FDA approved Zegalogue® (dasiglucagon) injection, for the treatment of severe hypoglycemia in children and adults with diabetes aged 6…
